AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteONT-093 is an orally bioavailable P-glycoprotein pump inhibitor, for the potential reversal of multidrug resistance in patients undergoing cancer chemotherapy.
More Information Supplier PageONT-093 is an orally bioavailable P-glycoprotein pump inhibitor, for the potential reversal of multidrug resistance in patients undergoing cancer chemotherapy.
More Information Supplier PageONX 0912 is a tripeptide epoxyketone, which inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies.
More Information Supplier PageONX 0912 is a tripeptide epoxyketone, which inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies.
More Information Supplier PageONX 0912 is a tripeptide epoxyketone, which inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies.
More Information Supplier PageONX 0912 is a tripeptide epoxyketone, which inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies.
More Information Supplier PageONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus. ONX 0914 was designed to be a potent inhibitor of the immunoproteasome with minimal cross-reactivity for the constitutive proteasome.
More Information Supplier PageONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus. ONX 0914 was designed to be a potent inhibitor of the immunoproteasome with minimal cross-reactivity for the constitutive proteasome.
More Information Supplier PageONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus. ONX 0914 was designed to be a potent inhibitor of the immunoproteasome with minimal cross-reactivity for the constitutive proteasome.
More Information Supplier PageONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus. ONX 0914 was designed to be a potent inhibitor of the immunoproteasome with minimal cross-reactivity for the constitutive proteasome.
More Information Supplier PageONX 0914 is an immunoproteasome inhibitor with potential treatment applications in autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease and lupus. ONX 0914 was designed to be a potent inhibitor of the immunoproteasome with minimal cross-reactivity for the constitutive proteasome.
More Information Supplier PageOPC21268 is a non-peptide AVP Receptor V (Vasopressin Receptor) antagonist that shows 1000-fold selectivity for V1 receptors over V2 receptors.
More Information Supplier PageOPC21268 is a non-peptide AVP Receptor V (Vasopressin Receptor) antagonist that shows 1000-fold selectivity for V1 receptors over V2 receptors.
More Information Supplier PageOPC21268 is a non-peptide AVP Receptor V (Vasopressin Receptor) antagonist that shows 1000-fold selectivity for V1 receptors over V2 receptors.
More Information Supplier PageOphiopogonin D is a new phenylpropanoid glycoside from Ophiopogon japonicus Ker-Gawl.
More Information Supplier PageOphiopogonin D is a new phenylpropanoid glycoside from Ophiopogon japonicus Ker-Gawl.
More Information Supplier PageOphiopogonin D is a new phenylpropanoid glycoside from Ophiopogon japonicus Ker-Gawl.
More Information Supplier PageOphiopogonin D’, extracted from Ophiopogon japonicus (Thunb.) Ker-Gawl. dried tuberous roots.
More Information Supplier PageOphiopogonin D’, extracted from Ophiopogon japonicus (Thunb.) Ker-Gawl. dried tuberous roots.
More Information Supplier PageOrg 27569 is a potent CB1 receptor allosteric modulator (pEC50 = 8.24).
More Information Supplier PageOrg 27569 is a potent CB1 receptor allosteric modulator (pEC50 = 8.24).
More Information Supplier PageOrg 27569 is a potent CB1 receptor allosteric modulator (pEC50 = 8.24).
More Information Supplier PageOrg 27569 is a potent CB1 receptor allosteric modulator (pEC50 = 8.24).
More Information Supplier PageOrg 27569 is a potent CB1 receptor allosteric modulator (pEC50 = 8.24).
More Information Supplier PageOridonin (Isodonol), an entkaurane diterpenoid isolated from Rabdosia rubescens, is an important traditional Chinese herbal remedy.
More Information Supplier PageOridonin (Isodonol), an entkaurane diterpenoid isolated from Rabdosia rubescens, is an important traditional Chinese herbal remedy.
More Information Supplier PageOridonin (Isodonol), an entkaurane diterpenoid isolated from Rabdosia rubescens, is an important traditional Chinese herbal remedy.
More Information Supplier PageOridonin (Isodonol), an entkaurane diterpenoid isolated from Rabdosia rubescens, is an important traditional Chinese herbal remedy.
More Information Supplier PageOridonin (Isodonol), an entkaurane diterpenoid isolated from Rabdosia rubescens, is an important traditional Chinese herbal remedy.
More Information Supplier PageOrientin is a flavone, a chemical flavonoid-like compound. It is the 8-C glucoside of luteolin
More Information Supplier PageOrientin is a flavone, a chemical flavonoid-like compound. It is the 8-C glucoside of luteolin
More Information Supplier PageOrientin is a flavone, a chemical flavonoid-like compound. It is the 8-C glucoside of luteolin
More Information Supplier PageOrientin is a flavone, a chemical flavonoid-like compound. It is the 8-C glucoside of luteolin
More Information Supplier PageOritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.
More Information Supplier PageOritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.
More Information Supplier PageOritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.
More Information Supplier PageOrlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice.
More Information Supplier PageOrlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice.
More Information Supplier PageOrlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice.
More Information Supplier PageOrlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice.
More Information Supplier PageOrlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice.
More Information Supplier Page
